According to OpenAI on X, drug development in the United States typically takes 10 to 15 years from target discovery to regulatory approval, and advanced AI can speed this up by expanding hypothesis space, revealing nonobvious connections, and improving early-stage decision making (source: OpenAI post, Apr 16, 2026). As reported by OpenAI, AI-driven literature synthesis, multi-omics analysis, and generative molecular design can reduce iteration cycles and prioritization errors in target identification and lead optimization, which creates business opportunities for biopharma to lower R&D costs and increase pipeline throughput. According to OpenAI, these capabilities help researchers move faster not only by efficiency gains but by enabling better hypotheses sooner, pointing to near-term advantages for partnerships between model providers and pharma in preclinical discovery.